We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$803K
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$673K |
| 2 |
Zai Lab
ZLAB
|
+$472K |
| 3 |
Stellus Capital Investment Corp
SCM
|
+$422K |
| 4 |
DRD
DRDGold
DRD
|
+$415K |
| 5 |
OXLC
Oxford Lane Capital
OXLC
|
+$359K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$1.16M |
| 2 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$664K |
| 3 |
BioNTech
BNTX
|
+$663K |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$645K |
| 5 |
Prothena Corp
PRTA
|
+$590K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
401
DELISTED
Kezar Life Sciences
KZR
| – | – |
-5,431
| Closed | -$324K |
|
402
NextCure
NXTC
$19.5M
| – | – |
-2,035
| Closed | -$244K |
|
403
Voyager Therapeutics
VYGR
$187M
| – | – |
-35,712
| Closed | -$168K |
|
|
TCDA
404
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-38,593
| Closed | -$204K |
|
|
OYST
405
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| – | – |
-14,995
| Closed | -$274K |
|
|
CALA
406
DELISTED
Calithera Biosciences, Inc
CALA
| – | – |
-3,058
| Closed | -$148K |
|
|
ODT
407
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| – | – |
-19,421
| Closed | -$66K |
|
|
CNST
408
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-9,500
| Closed | -$222K |
|
|
EFF
409
DELISTED
EATON VANCE FLOATING-RATE INCOME PLUS FUND
EFF
| – | – |
-17,104
| Closed | -$278K |
|
|
FPRX
410
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-17,112
| Closed | -$645K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.
Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.
- Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
- Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
- Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
- Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
- Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
- Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
- Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.